Otsuka Pharmaceutical Development & Commercialization, Inc.
4 clinical trials · 4 recruiting · INDUSTRY
Trials by Otsuka Pharmaceutical Development & Commercialization, Inc.
RECRUITINGPhase 3NCT06973577
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 30820 locations
ADHDAnxietyGeneralized Anxiety+1
RECRUITINGPhase 3NCT06894212
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 52220 locations
Schizophrenia
RECRUITINGPhase 3NCT06971731
A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU)
The goal of this Phase 3, randomized study is to assess the safety, efficacy, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adults (18 years of age or older) with...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 12020 locations
Phenylketonuria
RECRUITINGPhase 2NCT06637514
A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria
The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 101 location
Phenylketonuria (PKU)